ArticleInternational orthopaedics2019
Total hip arthroplasty in osteonecrosis secondary to sickle cell disease.
Article in International orthopaedics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Total hip arthroplasty in sickle cell disease: A systematic review and meta-analysis of functional outcomes and complications.Journal of clinical orthopaedics and trauma · 2025Article
- Postoperative complications and cost implications in sickle cell disease patients undergoing total hip arthroplasty: A national inpatient sample study.Journal of orthopaedics · 2025Article
- Subtrochanteric shortening osteotomy in adult sickle cell disease patients with cemented total hip arthroplasty for hip deformities secondary to childhood osteonecrosis: is healing a challenge?International orthopaedics · 2025Article
- Review
- Femoral neck fracture in sickle cell anemia: A comprehensive case study.Clinical case reports · 2024Article
- Total Hip Arthroplasty Complications in Sickle Cell Disease: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Survival of total hip arthroplasty (THA) in sickle cell disease.Archives of orthopaedic and trauma surgery · 2023Article
- Association and Risk Factors of Osteonecrosis of Femoral Head in Sickle Cell Disease: A Systematic Review.Indian journal of orthopaedics · 2022Review
- Sickle cell disease as an accelerated aging syndrome.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Dual mobility total hip replacement: a 15-year experience in Burkina Faso.The Pan African medical journal · 2022Article
- Total Hip Replacement in Sickle Cell Disease Patients with Avascular Necrosis of Head of Femur: A Retrospective Observational Study.Indian journal of orthopaedics · 2021Article
- Total hip arthroplasty for sickle cell osteonecrosis: guidelines for perioperative management.EFORT open reviews · 2020Review
- Total hip arthroplasty in sickle cell disease: a systematic review.EFORT open reviews · 2020Review
- Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management.Hematology. American Society of Hematology. Education Program · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease (SCD) is a multisystem disease, and the predominant articular manifestation is osteonecrosis (ON). Total hip arthroplasty (THA) is technically challenging, and the complication rates are high. In this retrospective study, we have analysed the outcome of THA in a cohort of patients with SCD at our institution. MATERIALS AND
methodsWe identified 34 THAs between 1999 and 2016 in 30 patients (mean age 37 years) from our SCD database. Co-morbidities, both sickle and non-sickle-related, were documented. Complications and indications for revision surgery were analysed.
resultsAn uncemented prosthesis was predominantly used. The mean follow-up was 10.5 years (range 1-18). Six patients had revision surgery (17.6%), 2 (5.8%) for Prosthetic Joint Infection (PJI), and 4 (11.7%) for osteolysis of the acetabular component.
conclusionOur revision rates were comparable to the published literature. Our combined sickle cell clinic and the coordinated multidisciplinary management have been successful in reducing morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.